JP2011524362A - 神経線維腫症用の置換ベンゾイミダゾール - Google Patents

神経線維腫症用の置換ベンゾイミダゾール Download PDF

Info

Publication number
JP2011524362A
JP2011524362A JP2011513674A JP2011513674A JP2011524362A JP 2011524362 A JP2011524362 A JP 2011524362A JP 2011513674 A JP2011513674 A JP 2011513674A JP 2011513674 A JP2011513674 A JP 2011513674A JP 2011524362 A JP2011524362 A JP 2011524362A
Authority
JP
Japan
Prior art keywords
alkyl
formula
halo
neurofibromatosis
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011513674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524362A5 (enExample
Inventor
スチュアート，ダリン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2011524362A publication Critical patent/JP2011524362A/ja
Publication of JP2011524362A5 publication Critical patent/JP2011524362A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011513674A 2008-06-13 2009-06-11 神経線維腫症用の置換ベンゾイミダゾール Withdrawn JP2011524362A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6115608P 2008-06-13 2008-06-13
US61/061,156 2008-06-13
PCT/US2009/046971 WO2009152288A1 (en) 2008-06-13 2009-06-11 Substituted benzimidazoles for neurofibromatosis

Publications (2)

Publication Number Publication Date
JP2011524362A true JP2011524362A (ja) 2011-09-01
JP2011524362A5 JP2011524362A5 (enExample) 2012-07-26

Family

ID=40956523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011513674A Withdrawn JP2011524362A (ja) 2008-06-13 2009-06-11 神経線維腫症用の置換ベンゾイミダゾール

Country Status (12)

Country Link
US (1) US20110092546A1 (enExample)
EP (1) EP2288354A1 (enExample)
JP (1) JP2011524362A (enExample)
KR (1) KR20110025827A (enExample)
CN (1) CN102065859B (enExample)
AU (1) AU2009257487B2 (enExample)
BR (1) BRPI0915106A2 (enExample)
CA (1) CA2726376A1 (enExample)
MX (1) MX2010013683A (enExample)
RU (1) RU2011100106A (enExample)
TW (1) TW201004621A (enExample)
WO (1) WO2009152288A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
JP6768639B2 (ja) 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド 好酸球又はマスト細胞関連障害の治療
KR101880015B1 (ko) 2017-12-08 2018-07-19 아주대학교산학협력단 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물
CA3126021A1 (en) 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
WO2022268158A1 (zh) * 2021-06-23 2022-12-29 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物治疗I型神经纤维瘤病的用途
US20250235458A1 (en) * 2021-10-08 2025-07-24 Universite Claude Bernard Lyon 1 Benzimidazole derivatives for use in the treatment or prevention of a histiocytosis or a craniopharyngioma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009541A (es) * 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
GB0609378D0 (en) * 2006-05-11 2006-06-21 Novartis Ag Organic compounds
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
US20100074897A1 (en) * 2006-12-01 2010-03-25 University Of Utah Research Foundation Methods and Compositions related to HIF-1 alpha
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
RU2011100106A (ru) 2012-10-27
CN102065859A (zh) 2011-05-18
TW201004621A (en) 2010-02-01
CA2726376A1 (en) 2009-12-17
WO2009152288A1 (en) 2009-12-17
KR20110025827A (ko) 2011-03-11
CN102065859B (zh) 2012-10-03
MX2010013683A (es) 2011-04-26
EP2288354A1 (en) 2011-03-02
US20110092546A1 (en) 2011-04-21
AU2009257487B2 (en) 2013-01-31
AU2009257487A1 (en) 2009-12-17
BRPI0915106A2 (pt) 2016-02-10

Similar Documents

Publication Publication Date Title
US11096947B2 (en) Combination products with tyrosine kinase inhibitors and their use
CN102065859B (zh) 用于神经纤维瘤病的取代的苯并咪唑类
WO2015084804A1 (en) Combination of mdm2 inhibitor and braf inhibitor and their use
JP6526789B2 (ja) 組み合わせ療法
US20110118309A1 (en) Use of hdac inhibitors for the treatment of hodgkin's disease
NO20120451L (no) Farmasøytisk kombinasjon omfattende 40-O-(2-hydroksyetyl)-rapamycin samt ko-middelet exemestan samt anvendelse derav
EP2391366B1 (en) Substituted benzimidazoles for the treatment of astrocytomas
WO2010009285A1 (en) Use of hdac inhibitors for the treatment of acute myeloid leukemia and/or myelodysplastic syndrome
HK40064964A (en) Combination products with tyrosine kinase inhibitors and their use
WO2014155268A2 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120608

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130910